Profound Medical’s TULSA Procedure Outperforms Robotic Surgery in Penile Length Preservation
Event summary
- Profound Medical’s TULSA Procedure showed no median change in penile length at 1 month post-treatment, compared to a 0.65 cm reduction with robotic radical prostatectomy.
- The CAPTAIN trial, which exceeded its enrollment target of 201 patients by treating 211, compared the two procedures in men with intermediate-risk prostate cancer.
- Primary safety endpoints previously showed TULSA’s superiority in preserving erectile function and urinary continence at 6 months.
- Results were presented at the Society of Robotic Surgery Annual Meeting on July 24, 2026.
The big picture
Profound Medical’s data challenges the dominance of robotic surgery in prostate cancer treatment, highlighting a shift toward minimally invasive, MRI-guided therapies that prioritize quality-of-life outcomes. The CAPTAIN trial results position TULSA as a compelling alternative for patients concerned about post-surgical side effects, potentially reshaping treatment protocols and reimbursement strategies in urology.
What we're watching
- Clinical Adoption
- How the CAPTAIN trial results will influence urologists' preference for TULSA over robotic surgery in intermediate-risk prostate cancer cases.
- Regulatory Impact
- Whether these findings accelerate regulatory approvals or reimbursement policies favoring MRI-guided therapies like TULSA.
- Market Expansion
- The pace at which Profound Medical can scale commercialization of the TULSA Procedure in global markets beyond North America and Europe.